NRX Pharmaceuticals, Inc. Logo

NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | US

Overview

Corporate Details

ISIN(s):
US0894821034 (+2 more)
LEI:
Country:
United States of America
Address:
1201 ORANGE STREET, 19801 WILMINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NANOVIRICIDES, INC. Logo
Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.
United States of America NNVC
Nasus Pharma Ltd Logo
Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.
United States of America NSRX
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Natera, Inc. Logo
Provides non-invasive cfDNA tests for oncology, women's health, and organ health.
United States of America NTRA

Talk to a Data Expert

Have a question? We'll get back to you promptly.